ERIC 2018 | The expanding role of MRD in CLL
Florence Cymbalista
• 25 Oct 2018
The role of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is expanding, as discussed here in this insightful interview with Florence Cymbalista, MD, PhD, of Avicenne Hospital, Bobigny, France. Dr Cymbalista adresses the consideration of routine use, as well as the future outlook for MRD in CLL. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
